Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (237)

« Back to Publications

Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY.

Malijan GB. et al, (2026), Am J Kidney Dis, 87, 553 - 563.e1

Kidney function and mortality in Mexico: prospective study of 130 000 adults

Aguilar Ramirez D. et al, (2026), Kidney Medicine

SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis.

Neuen BL. et al, (2026), JAMA, 335, 233 - 244

Effects Of Empagliflozin On Kidney And Cardiac Magnetic Resonance Imaging Measures In Patients With Chronic Kidney Disease: An EMPA-KIDNEY Mechanistic Substudy

ZHU D. et al, (2025), American Journal of Kidney Diseases

Cardiac Effects of Dapagliflozin in People with Chronic Kidney Disease.

Bartholdy KV. et al, (2025), NEJM Evid, 4

Effects of Sodium glucose co-transporter-2 inhibitors by diabetes status and level of albuminuria: a collaborative meta-analysis

STAPLIN N. et al, (2025), Journal of the American Medical Association (JAMA)

Glucose interference in urine biomarkers and implications for SGLT2 inhibition

Malijan G. et al, (2025), Kidney International Reports

Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study.

Turner M. et al, (2025), Hypertension (Dallas, Tex. : 1979)

Glucose interference in urine biomarkers and implications for SGLT2 inhibition

Malijan GB. et al, (2025), Kidney International Reports

Estimated glomerular filtration rate, albuminuria, and risk of infection: a collaborative meta-analysis of individual participant data.

Ishigami J. et al, (2025), EClinicalMedicine, 86

Individual Participant Level Meta-Analysis Of The Effects Of Empagliflozin On Conventional And Exploratory Acute And Chronic Kidney Outcomes

HERRINGTON W. et al, (2025), The Lancet Diabetes and Endocrinology

Individual Participant Level Meta-Analysis Of The Effects Of Empagliflozin On Conventional And Exploratory Acute And Chronic Kidney Outcomes

HERRINGTON W. et al, (2025), The Lancet Diabetes and Endocrinology

Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial

Zhou J. et al, (2025), EClinicalMedicine

Long-Term Effects of Empagliflozin in Chronic Kidney Disease. Reply.

Herrington WG. et al, (2025), N Engl J Med, 392, 2285 - 2286

Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)

HORBY P. et al, (2025), The Lancet Infectious Diseases

Load More

1
2
3
4
5
6
7
...
»